Search From Over Half a Million Titles


Pharmaceuticals and Healthcare » Pharmaceuticals » Infectious Disease

PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025

  • ID:RM0034527
  • Published: December-2016
  • Pages:499
  • GlobalData
1 of 3

PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025 Summary The hepatitis C virus (HCV) is a small, enveloped RNA virus that causes acute and chronic infections of the liver and, if left untreated, can result in fibrosis, permanent liver damage (cirrhosis), HCC, and eventually death. A member of the Flaviviridae viral family and hepacivirus genus, HCV can be classified into six major genotypes, with many additional subtypes within each genotype. While genotype 1 (GT1) causes almost half of HCV infections, all six major genotypes (GT1-6) are prevalent worldwide. The genetic diversity of HCV strains, even within the same host, originates from the low fidelity of the ribonucleic acid (RNA) polymerase, and is thought to account for viral resi........
Show More

1 of 3


1 Table of Contents 1 Table of Contents 11 1.1 List of Tables 18 1.2 List of Figures 25 2 Introduction 28 2.1 Catalyst 28 2.2 Related Reports 29 2.3 Upcoming Related Reports 29 3 Disease Overview 30 3.1 Etiology and Pathophysiology 31 3.1.1 Etiology 31 3.1.2 Pathophysiology 34 3.2 Symptoms 35 3.3 Prognosis and Quality of Life 36 4 Epidemiology 38 4.1 Disease Background 38 4.2 Risk Factors and Comorbidities 39 4.3 Global Trends 41 4.3.1 Diagnosed Incidence and Total Prevalence 42 4.3.2 Genotype 48 4.4 Forecast Methodology 48 4.4.1 Sources Used Tables 50 4.4.2 Forecast Assumptions and Methods 60 4.4.3 Sources Not Used 81 4.5 Epidemiological Forecast of HCV (2015-2025) 82 4.5.1 Total Prevalent Cases 82 4.5.2 Diagnosed Prevalent Cases 98 4.6 Discussion 113 4.6.1 Epidemiological Forecast Insight 113 4.6.2 Limitations of the Analysis 114 4.6.3 Strengths of the Analysis 115 5 Disease Management 117 5.1 Diagnosis Overview 117 5.1.1 Initial Diagnosis and Referral 117 5.1.2 Patient Assessment 118 5.1.3 Viral Assessment 119 5.2 Treatment Guildines 120 5.3 US 124 5.3.1 Diagnosis 125 5.3.2 Treatment Guidelines 126 5.3.3 Clinical Practice and Coverage 129 5.4 5EU 133 5.4.1 Diagnosis Overview 134 5.4.2 Treatment Guidelines Overview 134 5.5 France 137 5.5.1 Diagnosis 137 5.5.2 Clinical Practice 138 5.6 Germany 139 5.6.1 Diagnosis 139 5.6.2 Clinical Practice 139 5.7 Italy 140 5.7.1 Diagnosis 140 5.7.2 Clinical Practice 140 5.8 Spain 141 5.8.1 Diagnosis 141 5.8.2 Clinical Practice 142 5.9 UK 142 5.9.1 Diagnosis 142 5.9.2 Clinical Practice 143 5.10 Japan 145 5.10.1 Diagnosis 145 5.10.2 Clinical Practice 146 5.11 Brazil 148 5.11.1 Diagnosis 149 5.11.2 Clinical Practice 149 5.12 China 150 5.12.1 Diagnosis 151 5.12.2 Clinical Practice 152 6 Competitive Assessment 155 6.1 Overview 155 6.2 Strategic Competitor Assessment 158 6.3 Major Brands - Fixed-Dose Combination Direct-Acting Antivirals 161 6.3.1 Harvoni (Ledipasvir/Sofosbuvir) 161 6.3.2 Viekira Pak (Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir) and Technivie (Ombitasvir/Paritaprevir/Ritonavir) 173 6.3.3 Zepatier (Elbasvir/Grazoprevir) 187 6.3.4 Epclusa (Sofosbuvir/Velpatasvir) 198 6.4 Major Brands - Single Component Direct-Acting Antivirals 209 6.4.1 Sovaldi (Sofosbuvir) 209 6.4.2 Daklinza (Daclatasvir) 218 6.4.3 Olysio (Simeprevir) 228 6.5 Major Brands - Peginterferon and Ribavirin 238 6.5.1 Pegasys (Peginterferon alfa-2a) and PegIntron (Peginterferon alfa-2b) 238 6.5.2 Copegus, Rebetol, and Generic Ribavirin 247 6.6 Other Branded Direct-Acting Antivirals 251 6.6.1 Incivek (Telaprevir) and Victrelis (Boceprevir) 252 6.6.2 Sunvepra (Asunaprevir) 254 6.6.3 Exviera (Dasabuvir) 254 6.6.4 Vanihep (Vaniprevir) 255 7 Unmet Needs and Opportunity Analysis 256 7.1 Overview 256 7.2 Reducing the Overall Cost Burden of Direct-Acting Antiviral Treatment Algorithms 258 7.2.1 Unmet Need 258 7.2.2 Gap Analysis 260 7.2.3 Opportunity 263 7.3 Increasing Awareness of Hepatitis C Treatment Opportunities 264 7.3.1 Adjusting the Approaches Physicians Take with Hepatitis C 264 7.3.2 Awareness in the General Population 268 7.4 Expanding Treatment Access 270 7.4.1 Unmet Need 270 7.4.2 Gap Analysis 271 7.4.3 Opportunity 271 7.5 Improving Diagnosis Rates in Patients with Chronic Hepatitis C Infection 272 7.5.1 Unmet Need 272 7.5.2 Gap Analysis 274 7.5.3 Opportunity 275 7.6 Reducing Frequency and Severity of Adverse Events in All Patient Groups 276 7.6.1 Unmet Need 276 7.6.2 Gap Analysis 277 7.6.3 Opportunity 277 7.7 Enhanced Cure Rates in Difficult-to-Treat Patients 278 7.7.1 Unmet Need 278 7.7.2 Gap Analysis 279 7.7.3 Opportunity 280 7.8 Clinical Evalulation of Direct-Acting Antiviral Efficacy in Pediatric Patients 281 7.8.1 Unmet Need 281 7.8.2 Gap Analysis 281 7.8.3 Opportunity 282 8 Pipeline Assessment 283 8.1 Overview 283 8.2 Clinical Trial Mapping 285 8.2.1 Clinical Trials by Status and Phase 285 8.3 Promising DAA Regimens in Clinical Development 286 8.3.1 Sofosbuvir/Velpatasvir/Voxilaprevir 289 8.3.2 Glecaprevir/pibrentasvir 298 8.3.3 Asunaprevir/Beclabuvir/Daclatasvir 309 8.3.4 MK-3682A and MK-3682B 317 8.3.5 Odalasvir-Based Regimens 324 8.4 Other Products in Clinical Development 331 8.4.1 Investigational Therapies with Established MOAs 331 8.4.2 Investigational Therapies with Novel MOAs 334 8.4.3 Clinical Development Outside 9MM 336 9 Current and Future Players 338 9.1 Overview 338 9.2 Trends in Corporate Strategy 343 9.3 Company Profiles 349 9.3.1 Gilead Sciences 349 9.3.2 AbbVie 353 9.3.3 Merck 355 9.3.4 Janssen 357 9.3.5 Bristol-Myers Squibb 359 9.3.6 Roche 361 9.4 Additional Companies with Promising Drugs 363 9.4.1 Regulus Therapeutics 363 9.4.2 Presidio Pharmaceuticals 364 9.4.3 Trek Therapeutics 366 10 Market Outlook 367 10.1 Global Markets 367 10.1.1 Forecast 367 10.1.2 Drivers and Barriers - Global Issues 374 10.2 US 375 10.2.1 Forecast 375 10.2.2 Key Events 380 10.2.3 Drivers and Barriers 380 10.3 5EU 381 10.3.1 5EU 381 10.3.2 France 387 10.3.3 Germany 393 10.3.4 Italy 398 10.3.5 Spain 403 10.3.6 UK 408 10.4 Japan 413 10.4.1 Forecast 413 10.4.2 Key Events 417 10.4.3 Drivers and Barriers 417 10.5 Brazil 418 10.5.1 Forecast 418 10.5.2 Key Events 422 10.5.3 Drivers and Barriers 422 10.6 China 423 10.6.1 Forecast 423 10.6.2 Key Events 427 10.6.3 Drivers and Barriers 428 11 Appendix 429 11.1 Bibliography 429 11.2 Abbreviations 472 11.3 Methodology 477 11.4 Forecasting Methodology 477 11.4.1 Patient Populations 477 11.4.2 Drugs Included in Each Therapeutic Class 479 11.4.3 Launch and Patent Expiry Dates 480 11.4.4 General Pricing Assumptions 481 11.4.5 Individual Drug Assumptions 482 11.4.6 Generic Erosion 488 11.4.7 Pricing of Pipeline Agents 488 11.5 Primary Research - KOLs and Payers Interviewed for this Report 489 11.5.1 KOLs 489 11.5.2 Payers 493 11.6 Primary Research - Prescriber Survey 494 11.7 About the Authors 495 11.7.1 Analysts 495 11.7.2 Therapy Area Director 495 11.7.3 Epidemiologists 496 11.7.4 Global Director of Therapy Analysis and Epidemiology 497 11.8 About The Author 498 11.9 Disclaimer 498



List Of Tables

1.1 List of Tables Table 1: Modes of HCV Transmission 35 Table 2: Symptoms of Acute and Chronic HCV Infection 36 Table 3: Risk Factors and Comorbidities Associated with HCV Infection 40 Table 4: 9MM, Anti-HCV+ Total Prevalence from 1988-2015 42 Table 5: Hepatitis C Virus Genotype Description 48 Table 6: 9MM, Sources Used to Forecast Anti-HCV+ Total Prevalent Cases 50 Table 7: 9MM, Sources Used to Forecast HCV RNA+ Total Prevalent Cases 51 Table 8: 9MM, Sources Used to Forecast Anti-HCV+ Total Prevalent Cases by HCV Genotypes 52 Table 9: 9MM, Sources Used to Forecast HCV/HIV Co-Infection Cases Among Anti-HCV+ Total Prevalent Cases 54 Table 10: 9MM, Sources Used to Forecast HCV/HBV Co-Infection Cases Among Anti-HCV+ Total Prevalent Cases 55 Table 11: 9MM, Sources Used to Forecast Anti-HCV+ Diagnosed Prevalent Cases 56 Table 12: 9MM, Sources Used to Forecast HCV RNA+ Diagnosed Prevalent Cases 58 Table 13: 9MM, Sources Used for Anti-HCV+ Diagnosed Prevalent Cases by Liver Cirrhosis Status 60 Table 14: 9MM, Sources Not Used in Epidemiological Forecast for Anti-HCV+ Total Prevalent Cases 81 Table 15: 9MM, Anti-HCV+ Total Prevalent Cases, All Ages, Both Sexes, N, Selected Years 2015-2025 83 Table 16. 9MM, Anti-HCV+ Total Prevalent Cases, by Age, Both Sexes, N (Row %), 2015 85 Table 17: 9MM, Anti-HCV+ Total Prevalent Cases, by Sex, All Ages, N (Row %), 2015 87 Table 18: 9MM, Anti-HCV+ Total Prevalent Cases, by HCV Genotype, All Ages, N (Row %), Both Sexes, 2015 90 Table 19: 9MM, HCV RNA+ Total Prevalent Cases, All Ages, Both Sexes, N, Selected Years 2015-2025 92 Table 20. 9MM, HCV RNA+ Total Prevalent Cases, by Age, Both Sexes, N (Row %), 2015 94 Table 21: 9MM, HCV RNA+ Total Prevalent Cases, by Sex, All Ages, N (Row %), 2015 96 Table 22: 9MM, Anti-HCV+ Diagnosed Prevalent Cases, All Ages, Both Sexes, N, Selected Years 2015-2025 99 Table 23: 9MM, Age-Specific Anti-HCV+ Diagnosed Prevalent Cases, Both Sexes, N (Row %), 2015 101 Table 24: 9MM, Anti-HCV+ Diagnosed Prevalent Cases, by Sex, All Ages, N (Row %), 2015 103 Table 25: 9MM, HCV RNA+ Diagnosed Prevalent Cases, All Ages, Both Sexes, N, Selected Years 2015-2025 107 Table 26: 9MM, Age-Specific HCV RNA+ Diagnosed Prevalent Cases, Both Sexes, N (Row %), 2015 109 Table 27: 9MM, HCV RNA+ Diagnosed Prevalent Cases, by Sex, All Ages, N (Row %), 2015 111 Table 28: HCV Genotypes Prevalent in the 9MM 120 Table 29: General Standard of Care by HCV Genotype in 2015 122 Table 30: Treatment Guidelines for Hepatitis C 123 Table 31: Country Profile - US 124 Table 32: Recommended Treatment Options for Treatment-Na ve Patients in the US, 2016 128 Table 33: Country Profile - 5EU 133 Table 34: Recommended Treatment Options for Treatment-na ve Patients in the 5EU, 2016 136 Table 35: Country Profile - Japan 145 Table 36: Country Profile - Brazil 148 Table 37: Country Profile - China 150 Table 38: Leading Treatments for Hepatitis C, 2016 160 Table 39: Harvoni - Clinical Trials Supporting Regulatory Approval 162 Table 40: Product Profile - Harvoni 164 Table 41: Key Clinical Trials of Gilead s Harvoni 165 Table 42: Safety of Harvoni - Most Common AEs 169 Table 43: Harvoni SWOT Analysis, 2016 171 Table 44: Global Sales Forecasts ($m) for Harvoni, 2015-2025 173 Table 45: Viekira Pak and Technivie - Key Clinical Trials Supporting Regulatory Approval 175 Table 46: Product Profile - Viekira Pak and Technivie 177 Table 47: Efficacy of Viekira Pak and Technivie - SVR12, Key Phase III and Phase II Studies 179 Table 48: Safety of Viekira Pak and Technivie - Most Common AEs 183 Table 49: Viekira Pak and Technivie SWOT Analysis, 2016 185 Table 50: Global Sales Forecast ($m) for Viekira Pak, 2015-2025 186 Table 51: Zepatier - Key Clinical Trials Supporting Regulatory Approval 188 Table 52: Product Profile - Zepatier 191 Table 53: Efficacy of Zepatier - SVR12, Key Phase III and Phase II Clinical Trials 192 Table 54: Treatment-Emergent Amino Acid Substitutions Among Virologic Failures of Zepatier 194 Table 55: Safety of Zepatier - Most Common AEs 195 Table 56: Zepatier SWOT Analysis, 2016 197 Table 57: Global Sales Forecasts ($m) for Zepatier, 2015-2025 198 Table 58: Key Clinical Trials of Gilead s Epclusa 200 Table 59: Product Profile - Epclusa 203 Table 60: Efficacy of Epclusa - SVR12, Key Phase III Trials 204 Table 61: Safety of Epclusa - Most Common AEs 206 Table 62: Epclusa SWOT Analysis, 2016 207 Table 63: Global Sales Forecasts ($m) for Epclusa, 2015-2025 208 Table 64: Sovaldi - Clinical Trials Supporting Regulatory Approval 210 Table 65: Product Profile - Sovaldi 212 Table 66: Efficacy of Sovaldi - SVR12, Key Phase III Trials 213 Table 67: Safety of Sovaldi - Most Common AEs 216 Table 68: Sovaldi SWOT Analysis, 2016 217 Table 69: Global Sales Forecast ($m) for Sovaldi, 2015-2025 218 Table 70: Daklinza - Key Clinical Trials Supporting Regulatory Approval 221 Table 71: Product Profile - Daklinza 223 Table 72: Efficacy of Daklinza - SVR12, Key Phase IIb and III Trials 224 Table 73: Safety of Daklinza - Most Common AEs 226 Table 74: Daklinza SWOT Analysis, 2016 227 Table 75: Global Sales Forecast ($m) for Daklinza, 2015-2025 228 Table 76: Olysio - Key Clinical Trials Supporting Regulatory Approval 230 Table 77: Product Profile - Olysio 232 Table 78: Efficacy of Olysio - SVR12, Key Phase III and Phase II Trials 233 Table 79: Safety of Olysio - Most Common AEs in Clinical Trials 236 Table 80: Olysio SWOT Analysis, 2016 237 Table 81: Global Sales Forecasts ($m) for Olysio, 2015-2025 238 Table 82: Product Profile - Pegasys 241 Table 83: Product Profile - PegIntron 242 Table 84: Efficacy of Pegasys with or without Ribavirin Compared with Interferon Alfa-2b 243 Table 85: Efficacy of PegIntron Compared With Interferon Alfa-2b 244 Table 86: Pegasys and PegIntron SWOT Analysis, 2016 245 Table 87: Global Sales Forecast ($m) for Pegasys, 2015-2025 246 Table 88: Global Sales Forecast ($m) for PegIntron, 2015-2025 247 Table 89: Ribavirin SWOT Analysis, 2016 249 Table 90: Global Sales Forecast ($m) for Copegus, 2015-2025 250 Table 91: Global Sales Forecast ($m) for Rebetol, 2015-2025 251 Table 92: Summary of Other Branded DAAs, 2016 251 Table 93: Unmet Needs and Opportunities in Chronic Hepatitis C 258 Table 94: Hepatitis C Virus Infection - Late-Stage Pipeline, 2016 287 Table 95: Key Clinical Trials of Gilead s Sofosbuvir/Velpatasvir/Voxilaprevir Combination 291 Table 96: Product Profile - Sofosbuvir/Velpatasvir/Voxilaprevir 293 Table 97: Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Phase II Clinical Trials 294 Table 98: Sofosbuvir/Velpatasvir/Voxilaprevir SWOT Analysis, 2016 297 Table 99: Global Sales Forecast ($m) for Sofosbuvir/Velpatasvir/Voxilaprevir, 2015-2025 298 Table 100: Phase III Clinical Trials of AbbVie s Glecaprevir/Pibrentasvir Combination 300 Table 101: Product Profile - Glecaprevir/Pibrentasvir 302 Table 102: Efficacy of Glecaprevir/Pibrentasvir in Phase II Trials 303 Table 103: Most Common AEs of Glecaprevir/Pibrentasvir in Phase II Trials 306 Table 104: Glecaprevir/Pibrentasvir SWOT Analysis, 2016 308 Table 105: Global Sales Forecast ($m) for Glecaprevir/Pibrentasvir, 2015-2025 309 Table 106: Phase III Clinical Trials of BMS s Asunaprevir/Beclabuvir/Daclatasvir 310 Table 107: Product Profile - Asunaprevir/Beclabuvir/Daclatasvir 311 Table 108: Efficacy of Asunaprevir/Beclabuvir/Daclatasvir in Phase III Clinical Trials 312 Table 109: Efficacy of Asunaprevir/Beclabuvir/Daclatasvir in Japanese Patients 313 Table 110: Asunaprevir/Beclabuvir/Daclatasvir SWOT Analysis, 2016 316 Table 111: Global Sales Forecast ($m) for Asunaprevir/Beclabuvir/Daclatasvir, 2015-2025 317 Table 112: On-Going Phase II Clinical Trials of MK-3682A and MK-3682B 318 Table 113: Product Profile - MK-3682A and MK-3682B 319 Table 114: Efficacy of MK-3682A and MK-3682B in Phase II Trials 320 Table 115: MK-3682A and MK-3682B SWOT Analysis, 2016 323 Table 116: Global Sales Forecasts ($m) for MK-3682A and MK-3682B, 2015-2025 324 Table 117: Phase II Clinical Trials involving Achillion and Janssen s Odalasvir 325 Table 118: Product Profile - AL-335/odalasvir/simeprevir 326 Table 119: AL-335/Odalasvir/Simeprevir SWOT Analysis, 2016 329 Table 120: Global Sales Forecast ($m) for AL-335/Odalasvir/Simeprevir, 2015-2025 330 Table 121: Other Products in Clinical Development for HCV Infection, 2016 331 Table 122: Clinical Development outside 9MM, 2016 336 Table 123: Key Companies in the HCV Marketplace in the 9MM, 2016 341 Table 124: Gilead s HCV Portfolio Assessment, 2016 353 Table 125: AbbVie s HCV Portfolio Assessment, 2016 355 Table 126: Merck s HCV Portfolio Assessment, 2016 357 Table 127: Janssen s HCV Portfolio Assessment, 2016 359 Table 128: BMS HCV Portfolio Assessment, 2016 361 Table 129: Roche s HCV Portfolio Assessment, 2016 363 Table 130: Regulus HCV Portfolio Assessment, 2016 364 Table 131: Presidio s HCV Portfolio Assessment, 2016 365 Table 132:Trek Therapeutics HCV Portfolio Assessment, 2016 366 Table 133: Global (9MM) Sales Forecast ($m) for Hepatitis C, 2015-2025 370 Table 134: 9MM Chronic Hepatitis C Market - Drivers and Barriers, 2015-2025 374 Table 135: US Sales Forecast ($m) for Hepatitis C, 2015-2025 377 Table 136: Key Events Impacting Sales for Chronic Hepatitis C in the US, 2015-2025 380 Table 137: Chronic Hepatitis C Market - Drivers and Barriers in the US, 2015-2025 380 Table 138: 5EU Sales Forecast ($m) for Hepatitis C, 2015-2025 383 Table 139: Key Events Impacting Sales for Chronic Hepatitis C in the 5EU, 2015-2025 386 Table 140: Chronic Hepatitis C Market - Drivers and Barriers in the 5EU, 2015-2025 386 Table 141: France Sales Forecast ($m) for Hepatitis C, 2015-2025 389 Table 142: Key Events Impacting Sales for Chronic Hepatitis C in France, 2015-2025 392 Table 143: Chronic Hepatitis C Market - Drivers and Barriers in France, 2015-2025 392 Table 144: Germany Sales Forecasts ($m) for Hepatitis C, 2015-2025 394 Table 145: Key Events Impacting Sales for Chronic Hepatitis C in Germany, 2015-2025 397 Table 146: Chronic Hepatitis C Market - Drivers and Barriers in Germany, 2015-2025 397 Table 147: Italy Sales Forecast ($m) for Hepatitis C, 2015-2025 399 Table 148: Key Events Impacting Sales for Chronic Hepatitis C in Italy, 2015-2025 402 Table 149: Chronic Hepatitis C Market - Drivers and Barriers in Italy, 2015-2025 402 Table 150: Spain Sales Forecast ($m) for Hepatitis C, 2015-2025 404 Table 151: Key Events Impacting Sales for Chronic Hepatitis C in Spain, 2015-2025 407 Table 152: Chronic Hepatitis C Market - Drivers and Barriers in Spain, 2015-2025 407 Table 153: UK Sales Forecasts ($m) for Hepatitis C, 2015-2025 409 Table 154: Key Events Impacting Sales for Chronic Hepatitis C in the UK, 2015-2025 412 Table 155: Chronic Hepatitis C Market - Drivers and Barriers in the UK, 2015-2025 412 Table 156: Japan Sales Forecast ($m) for Hepatitis C, 2015-2025 414 Table 157: Key Events Impacting Sales for Chronic Hepatitis C in Japan, 2015-2025 417 Table 158: Chronic Hepatitis C Market - Drivers and Barriers in Japan, 2015-2025 417 Table 159: Brazil Sales Forecast ($m) for Hepatitis C, 2015-2025 419 Table 160: Key Events Impacting Sales for Chronic Hepatitis C in Brazil, 2015-2025 422 Table 161: Chronic Hepatitis C Market - Drivers and Barriers in Brazil, 2015-2025 422 Table 162: China Sales Forecast ($m) for Hepatitis C, 2015-2025 424 Table 163: Key Events Impacting Sales for Chronic Hepatitis C in China, 2015-2025 427 Table 164: Chronic Hepatitis C Market - Drivers and Barriers in China, 2015-2025 428 Table 165 Key Historical and Projected Launch Dates for Chronic Hepatitis C 480 Table 166 Key Historical and Projected Patent Expiry Dates for Chronic Hepatitis C 481 Table 167: High Prescribers Surveyed 494



List of Figures

1.2 List of Figures Figure 1: HCV Genome and Polyprotein Composition 32 Figure 2: HCV Lifecycle Overview 33 Figure 3: 9MM, Anti-HCV+ Total Prevalent Cases, All Ages, Both Sexes, N, Selected Years 2015-2025 83 Figure 4: 9MM, Anti-HCV+ Total Prevalent Cases, by Age, Both Sexes, N, 2015 86 Figure 5: 9MM, Anti-HCV+ Total Prevalent Cases, All Ages, by Sex, N, 2015 88 Figure 6: 9MM, Age-Standardized Anti-HCV+ Total Prevalence, All Ages, by Sex, %, 2015 89 Figure 7: 9MM, HIV and HBV Co-Infections Among Anti-HCV+ Total Prevalent Cases, All Ages, Both Sexes, N, 2015 91 Figure 8: 9MM, HCV RNA+ Total Prevalent Cases, All Ages, Both Sexes, N, Selected Years, 2015-2025 93 Figure 9: 9MM, HCV RNA+ Total Prevalent Cases, by Age, Both Sexes, N, 2015 95 Figure 10: 9MM, HCV RNA+ Total Prevalent Cases, by Sex, N, 2015 97 Figure 11: 9MM, Age-Standardized HCV RNA+ Total Prevalence, All Ages, by Sex, %, 2015 98 Figure 12: 9MM, Anti-HCV+ Diagnosed Prevalent Cases, All Ages, Both Sexes, N, Selected Years 2015-2025 100 Figure 13: 9MM, Age-Specific Anti-HCV+ Diagnosed Prevalent Cases, Both Sexes, N, 2015 102 Figure 14: 9MM, Anti-HCV+ Diagnosed Prevalent Cases, All Ages, by Sex, N, 2015 104 Figure 15: 9MM, Age-Standardized Anti-HCV+ Diagnosed Prevalence, All Ages, by Sex, %, 2015 105 Figure 16: 9MM, Anti-HCV+ Diagnosed Prevalent Cases by Liver Cirrhosis Status, All Ages, Both Sexes, N, 2015 106 Figure 17: 9MM, HCV RNA+ Diagnosed Prevalent Cases, All Ages, Both Sexes, N, Selected Years 2015-2025 108 Figure 18: 9MM, Age-Specific HCV RNA+ Diagnosed Prevalent Cases, Both Sexes, N, 2015 110 Figure 19: 9MM, HCV RNA+ Diagnosed Prevalent Cases, All Ages, by Sex, N, 2015 112 Figure 20: 9MM, Age-Standardized HCV RNA+ Diagnosed Prevalence, All Ages, by Sex, %, 2015 113 Figure 21: Hepatitis C - Clinical Trials by Status and Phase, 2016 286 Figure 22: HCV Infection Therapies - Phase II-III Pipeline, 2016 288 Figure 23: Competitive Assessment of Late-Stage Pipeline Agents for HCV Infection, 2015-2025 289 Figure 24: Clinical and Commercial Positioning of Sofosbuvir/Velpatasvir/Voxilaprevir 296 Figure 25: Clinical and Commercial Positioning of Glecaprevir/Pibrentasvir 307 Figure 26: Clinical and Commercial Positioning of Asunaprevir/Beclabuvir/Daclatasvir 315 Figure 27: Clinical and Commercial Positioning of MK-3682A and MK-3682B 322 Figure 28: Clinical and Commercial Positioning of Odalasvir-Based Regimens 328 Figure 29: Company Market Share in HCV, 2015 and 2025 342 Figure 30: Company Portfolio Gap Analysis in HCV, 2015-2025 343 Figure 31: Annual Global (9MM) Sales of DAAs, by Region, in 2015 and 2025 372 Figure 32: Annual Global (9MM) Sales of DAAs, by Brand, in 2015 and 2025 373 Figure 33: Annual Sales of DAAs in the US in 2015 and 2025 379 Figure 34: Annual Sales of DAAs in the 5EU in 2015 and 2025 385 Figure 35: Annual Sales of DAAs in France in 2015 and 2025 391 Figure 36: Annual Sales of DAAs in Germany in 2015 and 2025 396 Figure 37: Annual Sales of DAAs in Italy in 2015 and 2025 401 Figure 38: Annual Sales of DAAs in Spain in 2015 and 2025 406 Figure 39: Annual Sales of DAAs in the UK in 2015 and 2025 411 Figure 40: Annual Sales of DAAs in Japan in 2015 and 2025 416 Figure 41: Annual Sales of DAAs in Brazil in 2015 and 2025 421 Figure 42: Annual Sales of DAAs in China in 2025 426


1 of 3

Type Delivery Format Details
Hard Copy A printed copy of the report will be shipped to you.
CD-ROM The report will be shipped to you in CD ROM format.
SINGLE USER Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows one specific user access to the product.
SITE LICENSE Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows all users within a given geographical location of your organization access to the product.
ENTERPRISEWIDE Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows all employees within your organization in different geographic locations access to the product.
1 - 5 USERS Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows up to five users have access to the product.
1 – 10 USERS Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows up to ten users have access to the product.
1 – 15 USERS Electronic (PDF) The report will be delivered to your email address in PDF format. The license allows up to fifteen users have access to the product.
1 - 5 USERS Online Access (For Databases) Database is accessed online through a secure website. You will receive a username and password via email to access to the online directory. The license allows up to five users have access to the product.
1 - 10 USERS Online Access(For Databases) Database is accessed online through a secure website. You will receive a username and password via email to access to the online directory. The license allows up to ten users have access to the product.
1 - 15 USERS Online Access(For Databases) Database is accessed online through a secure website. You will receive a username and password via email to access to the online directory. The license allows up to fifteen users have access to the product.
1 - 5 USERS Electronic (Excel) The Excel spreadsheet will be emailed to you. The license allows up to five users have access to the product.

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a 1-10 user licence, allowing up to ten users have access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a 1-15 user licence, allowing up to fifteen users have access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a 1-15 user licence, allowing up to fifteen users have access to the product.